The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the world’s largest cancer conferences, where researchers present studies that can change the standard of cancer care. At the 2026 meeting, one pancreatic cancer study generated extraordinary excitement. The findings elicited a standing ovation, marking a major breakthrough for metastatic pancreatic cancer, a disease that has seen few meaningful treatment advances in recent decades.
Here’s what patients should know about the study.
Breakthrough trial nearly doubles survival for patients with advanced pancreatic cancer
The phase III RASolute 302 trial delivered one of the most exciting breakthroughs in pancreatic cancer treatment in years. For patients with metastatic pancreatic cancer whose disease had progressed after initial treatment, the investigational targeted therapy daraxonrasib nearly doubled median overall survival compared with standard chemotherapy (13.2 months versus 6.7 months) and doubled the time patients lived without their cancer worsening. The treatment also shrank tumors in nearly three times as many patients as chemotherapy alone.
Why is this such a big deal? Pancreatic cancer has long been one of the most difficult cancers to treat, and meaningful improvements in survival have been rare. Daraxonrasib is the first therapy targeting the RAS signaling pathway to show this level of benefit in a phase 3 pancreatic cancer trial, offering new hope for a disease that has historically had limited treatment options.
The drug was also associated with better quality of life and fewer treatment discontinuations than chemotherapy, leading experts at ASCO to describe the findings as a “game changer” and a potential new standard of care for patients with previously treated metastatic pancreatic cancer.
Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.
